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Although men with prostate cancer are living longer, they are not nec-
essarily living well, with symptom burden increasing and HRQoL
declining over time.1 For many men, the first five years after diagnosis
is marked by unmet needs, debilitating disease and treatment‐related
bowel, urinary and sexual symptoms.2 To date, few studies have
examined the trajectories of men over the 10 years after diagnosis.3
To advance survivorship care, it is crucial to understand what factors
drive long‐term (10 year) health outcomes after a prostate cancer
diagnosis. Accordingly, this study extends our previous research4 to
report physical and mental HRQoL, life satisfaction and symptom bur-









2.1 | Study setting and participants
This study of newly diagnosed adult men with prostate cancer was
conducted in Queensland, Australia. Sampling strategy and methodsPsycho‐Oncology. 2019;1–6. wileyonlinelibrary.com/jourare previously described.4 Ethical approval was obtained from the
Queensland University of Technology Human Research Ethics
Committee (Approval No.3629H). In total, 1291 men were
approached, 1064 consented, and 598 (56%) completed the final
10‐year questionnaire. Self‐administered questionnaires and
computer‐assisted telephone interviews were completed at baseline,
and 2,6,12,24,36,48,60,72,84,96,108 and 120 months after the com-
mencement of treatment.2.2 | Measures and statistical analyses
Participants' demographics and clinical characteristics have been pre-
viously described.4 Outcome measures included Disease‐specific
(Expanded Prostate Cancer Index Composite; EPIC) and HRQoL (Short
Form 36; SF‐36); Satisfaction with Life (Satisfaction with Life Scale;
SWLS) (see Figures 1a‐1c).5-7 Growth mixture models (GMMs) in
Mplus (Muthen and Muthen, 2015, Mplus User's Guide http://www.
statmodel.com/usersguide/chapter8.shtml) were adopted to identify
trajectory classes and predictors using 10‐year follow‐up data, with





• Many prostate cancer survivors face ongoing decrements
in health‐related quality of life (HRQoL)































































64were computed using multiple‐imputation (10 repetitions), but partic-
ipants with >9 missing values in EPIC or with missing data in other
predictors were excluded (sample size reduced to n=928). The number
of trajectory classes was determined using the Lo‐Mendell‐Rubin like-
lihood ratio test.• The long‐term trajectories of men with prostate cancer
are not well described
• To our knowledge, this is the first substantive prospective
study to track men's HRQoL, life satisfaction and
symptom burden ten years from diagnosis
• Androgen deprivation therapy (ADT), multiple
comorbidities, younger age and socioeconomic
disadvantage are risk indicators for poorer long‐term
HRQoL after prostate cancer.
• Risk indicators need to be incorporated into survivorship
care planning to facilitate personalised care for men most















3.1 | Quality of life – Physical health
Three trajectory classes were identified (Table 1a and Supplementary
File 1: Figures 1a and 2a). 35.0% of men experienced poor physical
HRQOL (Class 1; standardized effect sizes relative to Classes 2 or 3
greater than 0.6 at 5‐10 years after diagnosis). Compared with the
group of participants (38.9%) with constantly high QoL physical health
over 10 years (Class 3), Class 2 (lower physical HRQoL) was character-
ized by participants with ≥3 comorbid conditions (adjusted OR=3.29,
95% CI=1.33‐8.18) and participants who received external beamFIGURE 1 Trajectory patterns identified
using growth mixture models: A, quality of life
SF36, physical health domain (N=928); B,
quality of life SF36, mental health domain






































TABLE 1 Predictors of trajectory class membership for various outcome measures
Table 1(a): Quality of Life SF36 (Physical Health Domain, N=928)
Adjusted OR (95% CI) relative to Constant High class (Class 3)
Predictor Class 2 Class 1 P valuea
Household income <.001
<$40,000 1.82 (0.81, 4.06) 4.20* (2.01, 8.77)
$40,000 ‐ $80,000 2.13 (0.84, 5.40) 2.72* (1.25, 5.94)
>$80,000 Reference Reference
Not answer/don't know 1.50 (0.47, 4.81) 1.94 (0.72, 5.24)
Comorbidity <.001
0 condition Reference Reference
1‐2 conditions 1.13 (0.54, 2.36) 2.63* (1.32, 5.22)
≥3 conditions 3.29* (1.33, 8.18) 12.4* (5.27, 29.2)
Therapy performed vs nil <.001
Radical prostatectomy 0.66 (0.19, 2.25) 0.19* (0.08, 0.45)
External beam radiation 2.71* (1.36, 5.41) 0.76 (0.36, 1.61)
Brachytherapy 0.92 (0.30, 2.79) 0.27* (0.12, 0.64)
Hormone therapy 1.74 (0.64, 4.77) 2.96* (1.21, 7.23)
Watchful waiting 0.88 (0.20, 3.78) 0.63 (0.24, 1.66)
Table 1(b): Quality of Life SF36 (Mental Health Domain, N=928)
Adjusted OR (95% CI) relative to Constant High class (Class 3)
Predictor Class 2 Class 1 P valuea
Household income <.001
<$40,000 1.94* (1.03, 3.66) 2.62* (1.41, 4.89)
$40,000 ‐ $80,000 1.53 (0.80, 2.92) 1.18 (0.57, 2.42)
>$80,000 Reference Reference
Not answer/don't know 1.10 (0.43, 2.82) 0.98 (0.34, 2.86)
Comorbidity <.001
0 condition Reference Reference
1‐2 conditions 1.50 (0.80, 2.80) 3.41* (1.24, 9.44)
≥3 conditions 2.34* (1.14, 4.80) 6.25* (2.16, 18.09)
Table 1(c): Satisfaction with Life (SWLSM, N=928)
Adjusted OR (95% CI) relative to Constant High (Class 3)
Predictor Class 2 Class 1 P valuea
Age (Younger) 1.09* (1.04, 1.14) 1.01 (0.92, 1.11) <.001
Marital status
Married/defacto Reference Reference .004
Never married/widowed/ 2.55* (1.40, 4.65) 1.57 (0.72, 3.43)
divorced/separated
Household income <.001
<$40,000 2.86* (1.20, 6.79) 1.14 (0.33, 4.02)
$40,000 ‐ $80,000 1.99 (0.96, 4.09) 0.67 (0.22, 1.98)
>$80,000 Reference Reference
Not answer/don't know 0.86 (0.30, 2.49) 0.71 (0.24, 2.16)
(Continues)



















































































































Table 1(c): Satisfaction with Life (SWLSM, N=928)
Adjusted OR (95% CI) relative to Constant High (Class 3)
Predictor Class 2 Class 1 P valuea
Comorbidity <.001
0 condition Reference Reference
1‐2 conditions 1.63 (0.81, 3.27) 1.28 (0.48, 3.46)
≥3 conditions 3.39* (1.65, 6.95) 0.90 (0.23, 3.49)
*significant at 0.05 level on the adjusted log odds of being in the class versus Class 3
alikelihood ratio test (full model versus model without the predictor under consideration)
FIGURE 2 Effects from the expanded
prostate cancer index composite (EPIC)
urinary, bowel, and sexual functions on: A,
quality of life SF36, physical health domain (N
= 928); B, quality of life SF36, mental health
domain (N=928); C, satisfaction with life
(SWL) score (N=928)















































































































112radiation therapy (EBRT) (adjusted OR=2.71, 95% CI=1.36‐5.41). Alter-
natively, Class 1 (lowest QoL) was differentiated by participants with
lower household income (e.g., adjusted OR=4.20, 95% CI=2.01‐8.77
for income <$40,000), participants with high levels of comorbidity(e.g., adjusted OR=12.4, 95% CI=5.27‐29.2 for ≥3 comorbid condi-
tions), participants who did not receive RP (adjusted OR=0.19, 95%
CI=0.08‐0.45) or BT (adjusted OR=0.27, 95% CI=0.12‐0.64), and par-
ticipants who received ADT (adjusted OR=2.96, 95% CI=1.21‐7.23).113
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753.2 | Quality of life – Mental health
Three trajectory classes were identified (Table 1b and Supplementary
File 1: Figures 1b and 2b). 40.3% of men reported adverse mental
HRQOL (Classes 1 or 2; standardized effect sizes relative to Class
3 greater than 0.9 at 5‐10 years). Compared with the group of par-
ticipants (59.7%) with constantly high QoL mental health over 10
years (Class 3), Class 2 (lower mental‐health QoL) was characterized
by participants with lower household income (adjusted OR=1.94,
95% CI=1.03‐3.66 for income <$40,000) and participants with ≥3
comorbid conditions (adjusted OR=2.34, 95% CI=1.14‐4.80). Alterna-
tively, Class 1 (lowest QoL) was differentiated by participants with
lower household income (adjusted OR=2.62, 95% CI=1.41‐4.89
for income <$40,000) and participants with high levels of comorbid-















903.3 | Satisfaction with life
Three trajectory classes were identified (Table 1c and Supplementary
File 1: Figures 1c and 2c). 41.7% of men reported low life satisfaction
(Classes 1 or 2; standardized effect sizes relative to Class 3 greater
than 1.3 at 5‐10 years). Compared with the group of participants
(58.3%) who had constantly high SWL score throughout the 10‐year
follow‐up period (Class 3), Class 2 (low constant) was characterized
by participants who were younger age (adjusted OR=1.09 per 1‐year
decrease in age, 95% CI=1.04‐1.14), never married/widowed/
divorced/separated (adjusted OR=2.55, 95% CI = 1.40‐4.65), and par-
ticipants with household income <$40,000 (adjusted OR=2.86, 95%














1043.4 | Time‐varying effects of EPIC subscales
Generally, higher EPIC function significantly increased QoL and SWL
scores at each time point. The effects of EPIC bowel function on
the SF36 QoL physical and mental health were generally larger com-
pared to urinary and sexual functions; see4 for comparative results of
the 6‐year follow‐up data. For the SF36 QoL physical domain, the
effect of the EPIC urinary function started to decrease whereas that
of the EPIC sexual function started to increase after 8‐year post
diagnosis. For the SF36 QoL mental domain, the effects of all the
EPIC functions remained similar after 6‐year post diagnosis. For










Our findings indicate that 35 to 40% of men experience long term
decrements (ten years) in physical and mental quality of life outcomes
and life satisfaction after the diagnosis and treatment of prostate can-
cer. With gaps in prostate cancer survivorship interventions reportedin a recent review,3 urgent action is needed to improve ongoing care
for men with the disease.8
In particular, steps to ameliorate the side‐effects of ADT are
needed given the lasting effects of this treatment on men contributing
to poorer long‐term physical HRQoL. These steps may include inter-
ventions such as tailored exercise to reduce symptoms like fatigue,
sexual dysfunction, sarcopenia, and weight gain.9
Further support for socioeconomically disadvantaged and younger
men is needed with poorer ten‐year HRQoL most pronounced in men
who were younger, single, of lower income status, and living with
multiple comorbidities. Accordingly, these findings may reflect the
burden of disrupted life goals related to career development, impaired
relationship intimacy and greater financial responsibilities which may
fall more heavily upon younger or single men.10
4.1 | Clinical implications
These results provide a compelling case for routine, life‐long survivor-
ship care including physical and psychological symptom management
for men after a prostate cancer diagnosis. In our study, treatment with
ADT, the presence of multiple comorbidities, and socioeconomic dis-
advantage are risk indicators for poorer long‐term HRQoL and life sat-
isfaction after a prostate cancer diagnosis. Given a substantive group
with these factors reported constant comparatively poorer long‐term
outcomes over ten years, men should be assessed for these factors
and provided with suitable supportive care. Accordingly, we propose
men are comprehensively assessed soon after diagnosis, fully
informed of the short and long‐term implications of treatment choices
for their disease; supported in developing their own comprehensive
survivorship care plan; and referred to services for regular care and
support across the course of their disease.
4.2 | Limitations
Study limitations include using non‐probability sampling and not
having matched controls as a comparison group. Strengths of the
study include a large sample, application of well validated and reliable
measures, high response, an attrition rate comparable to similar stud-
ies a follow‐up of 10 years.5 | CONCLUSIONS
Over ten years, poorer long‐term HRQoL and life satisfaction were
associated with the use of ADT, multiple comorbidities, and low socio-
economic status. Since these factors predict poorer health outcomes,
men should be assessed for them and provided with life‐long prostate
cancer survivorship care.
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